PCOS has been renamed ‘PMOS’ – Polyendocrine Metabolic Ovarian Syndrome.
Here’s what the new name means, and why it changes everything….
If you were diagnosed with PCOS years ago, or you suspect you might have it now, you have probably heard that the name has changed. On 12 May 2026, following an eleven-year global consensus process involving more than 22,000 clinicians, researchers and patients, polycystic ovary syndrome – PCOS – was officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS.
I am Dr Sara Luck, and I see women with PMOS regularly at Essex Private Doctors. In my experience, the old name was unhelpful. Not because the condition had been misunderstood by patients, but because the label itself pointed everyone in the wrong direction. Cysts. Ovaries. A gynaecological problem. That framing left millions of women waiting too long for diagnosis, receiving fragmented treatment, and feeling dismissed when their symptoms did not fit the script.
PMOS is a better name. This article explains why, what is actually happening in your body, and what good care looks like.
Why the Name Changed from PCOS to PMOS
The old name – PCOS (Polycystic Ovary Syndrome) suggested that the defining feature of the condition was cysts on the ovaries. But that was always misleading. The so-called cysts are not cysts in the usual sense. They are small, immature follicles that began to develop but did not mature enough to release an egg.
More importantly, the ovaries are only one part of the picture. PMOS affects our whole body – the brain, the pancreas, the liver, fat tissue, the skin and the womb lining. In many women it also affects mental health and cardiovascular risk.
The new name tells a more accurate story:
- Polyendocrine: more than one hormone system is involved
- Metabolic: insulin resistance, weight regulation, inflammation and long-term metabolic risk are central features
- Ovarian: the ovary is involved, but is not the whole story
- Syndrome: the condition presents differently in different women
The consensus was published in the Lancet, presented at the European Congress of Endocrinology in Prague, and endorsed by more than 56 major organisations worldwide.
PMOS affects one in eight women. Around 70% of those women remain undiagnosed. The name change is, in part, an attempt to close that gap.
How a Normal Menstrual Cycle Works
In a normal menstrual cycle, the brain and ovaries maintain a carefully timed conversation using two key hormones.
FSH, follicle stimulating hormone, helps an egg follicle grow and mature. LH, luteinising hormone, triggers ovulation. FSH grows the egg. LH releases it.
Once ovulation occurs, the ovary produces progesterone, which stabilises the hormone environment and protects the womb lining. In PMOS, this rhythm is disrupted – and the disruption runs deeper than the ovary.
What Happens in PMOS – Polymetabolic Ovarian Syndrome
In PMOS, the brain’s hormone signalling becomes dysregulated. LH activity tends to be relatively high; FSH support is insufficient. This pushes the ovary towards producing androgens – hormones like testosterone – rather than reliably maturing and releasing an egg.
The follicles begin to develop but stall. This is called follicular arrest, and it produces the characteristic ultrasound appearance associated with the condition.
This can lead to irregular or absent ovulation, infrequent periods, elevated androgen levels, acne (particularly on the jawline and chin), facial or body hair growth, scalp hair thinning, and difficulty conceiving.
But this is still only part of the story.
Insulin Resistance: PMOS Metabolism
In many women with PMOS, including women who are not overweight, the body does not respond to insulin as efficiently as it should. The pancreas compensates by producing more.
High insulin stimulates the ovary to produce more testosterone. It also suppresses SHBG, sex hormone-binding globulin, the protein that binds testosterone and keeps it inactive. When SHBG falls, more testosterone is free and active in the body.
The pathway: insulin resistance drives higher insulin, which increases ovarian testosterone, which lowers SHBG, which worsens acne, facial hair, scalp thinning and ovulation disruption.
This is why PMOS is not a gynaecological condition that happens to affect hormones. It is a metabolic and endocrine condition that expresses itself through gynaecological, dermatological and reproductive symptoms.
Fat Tissue, Hunger and Why “Just Lose Weight” Is Unhelpful
Fat tissue behaves like a hormone-producing organ, releasing signals that affect insulin sensitivity and inflammation. When it becomes dysfunctional, particularly around the abdomen, it worsens the PMOS cycle.
PMOS is not caused by being overweight. Lean women can have PMOS and do. But in many women, weight gain and insulin resistance amplify the condition.
Leptin resistance – where the brain does not properly receive the signal that enough energy is stored – can cause increased hunger, reduced satiety and stronger cravings, even at a healthy weight. Combined with insulin resistance, this makes weight management in PMOS genuinely harder than it is for women without the condition. This is not a willpower problem. It is a hormone problem, and treating it as anything else is unhelpful.
Stress, Sleep, Cortisol and PMOS
Stress does not cause PMOS, but chronically elevated cortisol, poor sleep and sustained pressure can worsen nearly every feature of it: insulin resistance, central fat storage, cravings, inflammation and mood. Addressing these is not a cure, but it meaningfully reduces the load on a hormone network that is already under strain.
PMOS and Long-Term Health
PMOS is often discussed in terms of periods, fertility and skin. These matter enormously. But they are the visible surface of a condition with broader implications, including increased risk of prediabetes, type 2 diabetes, high blood pressure, cholesterol changes, fatty liver disease, sleep apnoea, cardiovascular disease, anxiety, depression, and endometrial thickening if periods are very infrequent.
PMOS should never be dismissed as a cosmetic issue or a fertility problem to revisit later. It is a lifelong condition requiring thoughtful, ongoing care.
No Two Women With PMOS Are the Same
For some women, the main presentation is irregular periods and acne. For others, it is facial hair or scalp thinning. For others, it is weight gain, fatigue, persistent hunger and insulin resistance. Some come to me because they cannot conceive. Others are managing the emotional weight of a condition that has affected their confidence for years.
Responses I would not accept as adequate for any of my patients: “Go on the pill.” “Lose weight and come back.” “Come back when you want to get pregnant.”
Good PMOS care means understanding the whole person: her symptoms, hormone profile, metabolic health, reproductive goals, mental wellbeing and long-term risks.
How PMOS Is Diagnosed
Diagnosis requires at least two of the following three features: irregular or infrequent periods; elevated androgens or signs of androgen excess such as acne or facial hair; and an excess of antral follicles on ultrasound. These are the Rotterdam criteria, which continue to apply under the new name.
A blood test measuring AMH, anti-Müllerian hormone, can now be used as an alternative to ultrasound. You do not need to have ovarian cysts seen on an ultrasound to be diagnosed.
Treatment Options for PMOS
Treatment should be matched to the features that matter most to that individual woman at that point in her life.
Lifestyle and metabolic support: Improving insulin resistance through nutrition, movement, resistance training, better sleep and stress management can meaningfully reduce androgen levels and improve cycle regularity. This is genuine first-line treatment.
Metformin: Improves insulin sensitivity and reduces the insulin-androgen loop. Useful for cycle regularity and long-term metabolic risk.
GLP-1 receptor agonists: Medications such as Mounjaro and Wegovy can help with appetite, weight management and insulin resistance in some women. They address the metabolic drivers of PMOS, not the follicles themselves.
Combined oral contraceptive pill: Reduces ovarian androgen production, raises SHBG, lowers free testosterone, protects the womb lining and regulates bleeding. A well-evidenced option for symptom control when pregnancy is not the current goal.
Spironolactone: Blocks the effect of testosterone at the skin and hair follicles. Useful for acne, facial hair and scalp thinning, and best used alongside broader metabolic management.
Endometrial protection: Women with very infrequent periods may need cyclical progesterone or the combined pill to protect the womb lining — not just for convenience, but for long-term womb health.
Fertility treatment: For women whose priority is conception, the approach shifts towards optimising ovulation, which may involve metabolic support, ovulation induction, or fertility referral.
PMOS Management at Essex Private Doctors
We offer specialist PMOS assessment at our clinic in Brentwood, Essex, seeing patients from across Chelmsford, Billericay, Colchester and the surrounding area.
A PMOS consultation is an in-depth assessment. We take a detailed history covering your cycle pattern, skin and hair symptoms, weight history, energy, sleep, stress, mental health and family history of diabetes or heart disease. Where necessary, we’ll arrange appropriate blood tests – androgens, insulin resistance markers, thyroid function and broader hormonal assessment – and explain what the results mean in plain terms.
Florence Rowe, our registered dietitian, is an expert in giving metabolic and nutritional support for women wanting to manage their PMOS better.
If you are in Essex and looking for specialist PMOS care, we would be glad to help.
Dr Sara Luck MBBS MRCGP DRCOG BSc
As a GP, I offer comprehensive care with a focus on lifestyle medicine—an approach that emphasises health optimisation and disease prevention through sustainable lifestyle changes.
Frequently Asked Questions About PMOS
Has PCOS officially been renamed?
Yes. On 12 May 2026, polycystic ovary syndrome was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), following an eleven-year global consensus process published in the Lancet and endorsed by more than 56 major organisations worldwide.
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome — the new official name for what was previously called PCOS.
Do I (still) have PMOS if I was diagnosed with PCOS?
Yes. PMOS and PCOS are the same condition under different names. Your diagnosis still stands; only the name has changed.
Do I need to have ovarian cysts to have PMOS?
No. Many women with PMOS do not have visible cysts. The follicles associated with the condition are small and immature — not true cysts in the medical sense. This was one of the key reasons the name was changed.
What are the symptoms of PMOS?
Symptoms vary and can include irregular or absent periods, acne (particularly on the jawline and chin), facial or body hair growth, scalp hair thinning, difficulty conceiving, fatigue, difficulty managing weight, strong cravings, anxiety and low mood.
Can you have PMOS if you are not overweight?
Yes. PMOS affects women of all body types. Weight is not a cause of PMOS, and being slim does not rule it out.
Is PMOS curable?
PMOS is a lifelong condition, but it is very manageable. Many women achieve good symptom control, regular cycles and significantly reduced long-term health risk with appropriate care.
Can PMOS affect mental health?
Yes. Women with PMOS have higher rates of anxiety and depression than the general population. Mental wellbeing is a valid and important part of PMOS care.
How is PMOS diagnosed?
Diagnosis requires at least two of the following: irregular or infrequent periods; elevated androgens or signs of androgen excess; and excess antral follicles on ultrasound or elevated AMH on a blood test.
What is the difference between PMOS and PCOS?
They are the same condition. PCOS was the previous name; PMOS is the new official name adopted in May 2026, chosen to better reflect the hormonal and metabolic complexity of the condition.
References and further reading
Teede H et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 12 May 2026.
Polyendocrine Metabolic Ovarian Syndrome (PMOS): new name for PCOS. Society for Endocrinology
